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SIRT1Alzheimer's disease (AD) is a devastating disorder that strikes 1 in 10 Americans over the age of 65, and almost
half of all Americans over 85 years old. The odds of an individual developing AD double every ﬁve years after the
age of 65. While it has become increasingly common to meet heart attack or cancer survivors, there are no AD
survivors. There ismounting evidence that dietary polyphenols, including resveratrol, may beneﬁcially inﬂuence
AD. Based on this consideration, several studies reported in the last few years were designed to validate sensitive
and reliable translational tools to mechanistically characterize brain bioavailable polyphenols as disease-
modifying agents to help prevent the onset of AD dementia and other neurodegenerative disorders. Several re-
search groups worldwide with expertise in AD, plant biology, nutritional sciences, and botanical sciences have
reported very high quality studies that ultimately provided the necessary information showing that polyphenols
and their metabolites, which come from several dietary sources, including grapes, cocoa etc., are capable of
preventing AD. The ultimate goal of these studies was to provide novel strategies to prevent the disease even be-
fore the onset of clinical symptoms. The studies discussed in this review article provide support that the informa-
tion gathered in the last few years of research will have a major impact on AD prevention by providing vital
knowledge on the protective roles of polyphenols, including resveratrol. This article is part of a Special Issue en-
titled: Resveratrol: Challenges in translating pre-clinical ﬁndings to improved patient outcomes.
© 2014 Elsevier B.V. All rights reserved.1. Polyphenols as novel “natural drug” agents in the prevention and
possible therapy of Alzheimer's disease
A notable example of one of the ﬁrst achievements from ongoing
investigations on the role of polyphenols in Alzheimer's disease (AD)
is the demonstration that polyphenols from select red wines, including
resveratrol, may help attenuate AD dementia by modulating β-amyloid-activated protein kinase; AD,
PP,Bioactivedietarypolyphenol
CaM-dependent protein kinase
; CVD, Cardiovascular disease;
in-1; cAMP, Cyclic adenosine
kinase B1; MCI, Mild cognitive
Parkinson's disease; PGC-1α,
rotein kinasemechanistic target
Amyloid
atrol: Challenges in translating
y, The Mount Sinai School of
, NY 10029, USA. Tel.: +1 212
etti).(Aβ) neuropathology through the inhibition of both Aβ generation
and abnormal Aβ oligomerization and through the promotion of Aβ
clearance, and by modulating tau neuropathology through the inhibi-
tion of abnormal tau phosphorylation and tau aggregation [29,30,32,
33,43,45,46,66,71,73–76]. All of these Aβ and tau mechanisms are key
therapeutic targets for AD. While polyphenols from certain red wines
inhibit Aβ aggregation, others do not [29,32]. These studies were con-
ducted a few years ago, and provided, for the ﬁrst time, the basis for
subfractionation of complex grape-derived polyphenol preparations
into increasingly less complex isolates for use in bioactivity studies,
in vitro and in vivo [30,70]. Recent fractionation studies have also re-
vealed that a grape seed polyphenolic extract (GSPE) is capable of
signiﬁcantly attenuating AD-type phenotypes in transgenic AD mice,
primarily due to its ability to increase the bioavailability of ﬂavan-3-ol
molecules (e.g., catechin, epicatechin, etc.) in the brains [22,70,73].
Interestingly, it was also reported that quercetin-3-O-glucuronide,
from red wines and Concord grape juice, is capable of reaching the
brain and contributes to protection against AD by modulating multiple
mechanisms, including by: reducing Aβ generation, reducing Aβ
oligomerization, and promoting neuroplasticity processes [30]. Notably,
other studies revealed that resveratrol may promote intracellular Aβ
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[64]. Overall, outcomes from these studies support the notion that au-
tophagy and inﬂammation work in concert with respect to the anti-
amyloidogenic effect of resveratrol. Moreover, recent studies suggest
that polyphenols may also reduce abnormal tau hyperphosphorylation
and tau aggregation [29,32,71,75,76]. A major achievement in the
search for the role of polyphenols in AD prevention and therapies is
the ﬁnding that multiple polyphenol metabolites, derived from dietary
polyphenols, are able to cross the blood–brain barrier (BBB) and to
penetrate and accumulate in the brain at pharmacologically relevant
sub-μM to μM concentration [22,30,77]. Moreover, we found that
certain brain-penetrating polyphenols are capable of modulating AD
neuropathogenic mechanisms. For example, we found that one of the
brain-penetrating polyphenol metabolites, quercetin-3-O-glucoside, is
capable of modulating Aβ neuropathogenic mechanisms [30]. More-
over, we found that another brain-penetrating polyphenol metabolite,
3′-O-methyl-epicatechin-5-O-β-glucuronide, is capable of directly
modulating synaptic plasticity by promoting cAMP response element-
binding protein (CREB) signal transduction, which is involved in
mechanisms associated with learning and memory functions [30,70].
Based on these ﬁndings, we proposed that the dietary polyphenol
preparations that we studied are able to modulate AD through the
activities of their brain-penetrating polyphenol preparations, which
modulate multiple pathogenic processes such as Aβ and tau neuro-
pathogenic mechanisms, neuroplasticity, and inﬂammation (see Fig. 1).
These scientiﬁc achievements are indicators of the widespread
success of research in polyphenols in AD. Most excitingly, for the ﬁrst
time, these studies provided the basis for translational investigations
into clinical studies exploring the feasibility of developing select
polyphenols for preventative strategies in AD. As discussed further
below, this increasing interest in the ﬁeld of polyphenols is reﬂected
by 85 currently listed clinical trials in the NIH clinicaltrials.gov registry
exploring the role of resveratrol in several conditions, including 5
studies in AD and 29 on the role of type 2 diabetes (T2D) in cognitive
functions associated with aging. This evidence strongly supports the
widespread mounting interest in the role of polyphenols, including
the use of resveratrol for prevention and treatment of AD and age-
related cognitive deterioration.Brain-penetrating, bioactiv
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Fig. 1. Brain-penetrating polyphenol metabolites derived from certain bioactive dietary polyph
mechanisms, neuroplasticity, and inﬂammatory mechanisms.2. Resveratrol, inﬂammation, and type 2 diabetes: implications in
metabolic disturbances associated with the onset and progression
of AD
A large body of literature has shown that resveratrol, a naturally
occurring polyphenol (trans-3,4′,5-trihydroxystilbene), exerts beneﬁ-
cial effects on AD, an age-related neurodegenerative condition that in
some cases is also comorbid with certain metabolic disorders, such as
type 2 diabetes and obesity [6,38]. Resveratrolmimics caloric restriction
by extending the lifespan of several small organisms [7,25], and by
delaying speciﬁc age-related phenotypes, e.g., abnormal glucose
metabolism [51]. Resveratrol is also thought to beneﬁcially inﬂuence
cognitive deterioration [2,54]. Clinical studies are underway to explore
the beneﬁts of resveratrol for treating individuals with dementia,
particularly those characterized by mild cognitive impairment (MCI), a
clinical condition that eventually progresses to AD.
The direct molecular targets of resveratrol, in vitro and in vivo, are
unknown. The compound has been suggested to modulate cellular
processes by activating key metabolic sensor/effector proteins, includ-
ing AMP-activated protein kinase (AMPK), sirtuin 1 (SIRT1), and
peroxisome proliferator-activated receptor γ co-activator-1α (PGC-1α)
[11,12,62,63,64]. It was initially proposed that resveratrol binds
in vitro to SIRT1 and activates the deacetylase activity of this enzyme
[34]. However, recent studies have challenged these data by showing
that the reported direct interaction between resveratrol and SIRT1
in vitro was likely an artiﬁcial observation, implying that resveratrol
might act in vivo by targeting other proteins [9,48]. Nevertheless,
SIRT1 appears to be required for resveratrol metabolic functions
in vivo by contributing to an energy sensing network involving AMPK
and PGC-1α [11,12,59].
Resveratrol has been shown to have beneﬁcial effects in in vitro
models of epilepsy, Alzheimer's disease (AD), Parkinson's disease
(PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS),
and nerve injury [58]. AMPK, SIRT1, and PGC-1α were all thought to
be involved in the etiology of these neurological disorders. Based on
evidence that resveratrol modulates these proteins, it was proposed
that resveratrol has therapeutic potential in the above-mentioned
neurodegenerative diseases. The therapeutic potential of resveratrol ine phenolic compounds
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strating neuroprotective effects of resveratrol in different cell culture
and in vitro systems [65].3. Bioavailability and clinical trials of resveratrol in Alzheimer's dis-
ease and other neurodegenerative diseases
The bioavailability of resveratrol has received considerable attention
[68]. The oral bioavailability of resveratrol is rather low; less than 1%.
Micronized resveratrol also has low systemic availability, although it
can reach levels 3.6 times higher than that of the standard form [33].
Although in vivo evidence is emerging in animalmodels that resveratrol
is bioavailable [66] and bioactive [36,66] in the brain, conclusive results
in human trials are still lacking. Due to resveratrol's very low bioavail-
ability and how rapidly it is metabolized, it has been suggested that
some of its metabolites may be responsible for its biological activity. In
particular, resveratrol-3-sulfate and resveratrol-3-O-glucuronide are
themajormetabolites of resveratrol, and di- and tri-sulfated derivatives
have been also detected in substantial concentrations in vivo [78].
There are currently as many as 85 clinical trials listed in the
NIH clinicaltrials.gov registry that investigate the effect of resveratrol
on diverse conditions including 5 involving AD and others involving
several conditions associated with AD, for example, type 2 diabetes
and cognitive performance (memory) in the elderly, among others
(see Table 1 for a list of selected clinical trials). Interestingly, a phase II
study of 119 individuals with mild to moderate AD, although under-
powered to detect clinical beneﬁts, found that resveratrol was safe
and generally well-tolerated at doses up to 1 g orally twice daily.
While minor side effects were reported, including gastrointestinal
nausea and diarrhea, the data analyses are nowunderway. The available
information at this point is that there are alterations in some cerebrospi-
nal ﬂuid and plasma proteins, as well as in volumetric imaging
outcomes, in the resveratrol-treated group compared to the placebo-
treated group (clinicaltrials.gov identiﬁer NCT01504854). Furthermore,
we note that there are also 29 clinical trials, some of which are listed
in Table 1, related to the potential therapeutic role of resveratrol in
T2D and other features of metabolic syndrome. As we discuss below,
recent studies are testing the hypothesis that resveratrol and other
polyphenols may improve cognitive performance in neurological con-
trols and possibly delay the onset of MCI, and eventually its progression
to AD, through control of peripheral glucose metabolism.Table 1
Selected clinical trials from the NIH clinicaltrials.gov registry that investigate the effects of res
AD = Alzheimer's disease; T2D = type 2 diabetes.
Status Study
Active, not recruiting Resveratrol for AD
Completed Randomized Trial of a Nutritional Supplement in AD
Unknown Pilot Study of the Effects of Resveratrol Supplement in Mild-to-Mo
Recruiting Short Term Efﬁcacy and Safety of Perispinal Administration of Etan
Recruiting Effects of Dietary Interventions on the Brain in Mild Cognitive Imp
Completed Resveratrol–Leucine Metabolite Synergy in Pre-diabetes
Completed Effects of Resveratrol in Patients With T2D
Active, not recruiting Resveratrol in T2D and Obesity
Active, not recruiting Resveratrol and T2D
Recruiting Effect of Resveratrol on Age-related Insulin Resistance and Inﬂamm
Recruiting Resveratrol and the Metabolic Syndrome
Completed Dietary Polyphenols and Lipid Oxidation
Unknown Pilot Study of Resveratrol in Older Adults With Impaired Glucose T
Completed Effect of Resveratrol Administration on Metabolic Syndrome, Insul
Recruiting Resveratrol and the Metabolic Syndrome
Recruiting Resveratrol in Metabolic Syndrome
Withdrawn Mechanisms of Metabolic Regulation of Resveratrol on Humans W
Completed Long-term Investigation of Resveratrol in Obesity
Completed Potential Beneﬁcial Effects of Resveratrol
Recruiting The Effects of Red Wine Polyphenols on Microvascular Dysfunction4. Does resveratrol work through activation of SIRT1?
Resveratrol and SIRT1 are best known for their pro-longevity
properties. Studies in Saccharomyces cerevisiae, Caenorhabditis elegans,
and Drosophila have established SIRT1 orthologs as key determinants
of longevity [23]. In several models, the effects of calorie restriction on
lifespan extension were proposed to be SIRT1-dependent [23]. Resvera-
trol was also found to mimic calorie restriction at the molecular level
and to extend longevity in both yeast and in worms [7,25]. SIRT1 was
thought to be the molecular target of resveratrol, based on in vitro
studies showing that the polyphenol can enhance SIRT1 deacetylase ac-
tivity [34]. Concerns have been raised, however, about the validity of the
enzymatic assay used in this study. Indeed, consecutive studies have
shown that resveratrol does not activate SIRT1 in vitro, and thus is likely
to work through direct interaction with one or several other proteins
in vivo [8,9,48]. Resveratrol is a relatively potent activator of AMPK in
cell cultures and in vivo in mice [11,12,19,27,66]. Resveratrol's effect
on AMPK activity was proposed to be indirect as well, either by increas-
ing cytosolic calcium levels [66] or by facilitating AMP-dependent
activation of AMPK [27]. Nevertheless, AMPK activation by resveratrol
is dependent on sirtuin function. Also, SIRT1 appears to be required
for resveratrol metabolic functions in skeletal muscle in vivo, by
contributing to the activation of AMPK as well as PGC-1α, which is a
downstream substrate of SIRT1 [11,12,59]. In spite of evidence implicat-
ing resveratrol as having the potential to modulate the AMPK/SIRT1/
PGC-1α signaling network, the direct in vivo molecular target(s) of
resveratrol remain(s) elusive.
5. Polyphenols and resveratrol in AD and other neurodegenerative
disorders
Resveratrol is found naturally in low concentrations among certain
food sources such as peanuts, some berries, red grapes, and grape by-
products such as red wines and red grape juices [10,57,60]. Prospective
studies have shown that moderate red wine consumption is associated
with a lower relative risk of dementia [47]. More recently, James Joseph
and colleagues demonstrated that dietary supplementation with a
Concord purple grape juice signiﬁcantly improves memory function in
subjects with mild cognitive impairment [37]. Consistent with these
observations, we demonstrated that moderate red wine consumption
beneﬁcially modulates AD-type cognitive deterioration in the Tg2576
transgenic mouse model of AD by attenuating Aβ neuropathology [29,veratrol on Alzheimer's disease and diabetes and/or metabolic syndrome. Abbreviations:
Conditions
AD
AD
derate AD AD
ercept in Mild to Moderate AD AD
airment (MCI) Mild cognitive impairment
Impaired glucose tolerance
T2D
T2D; obesity; insulin resistance
T2D
ation in Humans T2D mellitus; insulin resistance
Obesity; insulin resistance; metabolic syndrome
Obesity; insulin sensitivity; T2D mellitus
olerance Impaired glucose tolerance
in Sensitivity and Insulin Secretion Metabolic syndrome X
Obesity; insulin resistance; metabolic syndrome
Metabolic syndrome
ith Metabolic Syndrome Insulin resistance
Obesity; inﬂammation; insulin sensitivity;
osteoporosis
Metabolic syndrome; obesity
Obesity
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from red wine signiﬁcantly attenuate the generation of Aβ peptide in
primary cortico-hippocampal neuron cultures generated from Tg2576
mice [74].While redwine and grape juice are among some of the richest
dietary sources of resveratrol, we found that the content of resveratrol
in redwines or grape juices cannot account for the neurological beneﬁts
derived from normal consumption of red wine (or grape juice). For
example, while resveratrol has been found to promote Aβ clearance
[43], the content of resveratrol in the red wine we used in the Wang
et al. [74] study is approximately 10-fold lower than the minimal
effective concentration shown to promote Aβ clearance in vitro [43].
Thus, these studies suggest that grape-derived polyphenolic com-
ponents other than resveratrol may also exert neurological health
beneﬁts. Consistent with this, we demonstrated that a red wine poly-
phenolic preparation containing no detectable contents of resveratrol
signiﬁcantly attenuates the development of β-amyloid neuropathology
and cognitive deterioration in Tg2576 AD mice [29,32]. Collectively,
our observations raise an intriguing possibility that a combination of
grape-derived polyphenolics may modulate AD by simultaneously
reducing Aβ generation, interfering with aggregation of Aβ peptides,
and/or promoting molecular mechanisms involved in memory
consolidation.
Our observation that certain red wine polyphenolic preparations
potently interfere with aberrant aggregation of Aβ peptides also has
implications for other neurodegenerative disorders. Abnormal aggrega-
tion of certain proteins in susceptible brain cells is a common feature of
a number of neurodegenerative disorders, including AD, PD, ALS, and
HD. Recent evidence indicates that mutant huntingtin (htt) aggregation
in susceptible brain cells may be responsible for the onset and progres-
sion of the HD-type phenotype [41,83], implicating abnormal htt
protein aggregation as a novel target for HD treatment. We recently
found that a grape-derived polyphenolic preparation interferes with
abnormal aggregation of htt protein in an in vitro cell model of HD
degeneration [71,75,76]. Collectively, accumulating evidence from our
group and others provides the motivation for further investigations
to explore, pre-clinically, the suitability of alternative grape-derived
polyphenols as potential novel agents for the treatment of AD and
other neurodegenerative conditions also caused by abnormal protein
aggregation.
A recent study [49] examined the therapeutic potential of a
micronized proprietary resveratrol formulation, SRT501, in the N171-
82Q transgenicmousemodel of HD. HD is a progressive and devastating
genetic neurodegenerative disorder that is associatedwith downregula-
tion of PGC-1α activity. The study found that SRT501 treatment did not
lead to signiﬁcant improvement in weight loss, motor performance,
survival, or striatal atrophy. However, other studies have reported
neuroprotective effects of resveratrol and a distantly related poly-
phenol, ﬁsetin, in HD models. An interesting connection is that HD has
been associated with diabetes mellitus. Interestingly, evidence from
the Ho et al. study suggests that the resveratrol formulation induced
beneﬁcial anti-diabetic effects in N171-82Q mice. The observation that
oral SRT501-M treatment induced biological responses in the cortex
but not in the striatum is consistent with previous studies that found
that orally administered resveratrol can cross the BBB and accumulate
in the cerebral cortex, but not in the hippocampus [36,66]. This selective
accumulation of resveratrol in different brain regions remains unex-
plained, but may be due to the diffusion rate of the compound or to
its speciﬁc metabolism in the brain. Nevertheless, the [49] studies
indicate that resveratrol should be tested further in HD, and that
improved administration and formulation methods must be imple-
mented and more potent resveratrol metabolites or analogues should
be identiﬁed prior to evaluation in animal models.
A recent study by [42] in HD models reported neuroprotective
effects of two polyphenols: resveratrol, in vitro, and ﬁsetin, in vivo.
Resveratrol was found to be ineffective in the N171-82Q HD mouse
model, whereas ﬁsetin was neuroprotective in vivo in the R6/2 mousemodel of HD. However, ﬁsetin is rather distantly related to resveratrol,
and thus the in vivo ﬁsetin data cannot be extrapolated towards resver-
atrol. It remains to be established whether other formulations or dosing
regimens of the compound would have efﬁcacy in animal models and
human clinical trials for HD.
6. SIRT1 and Alzheimer disease
A main pathogenic event in AD is the cerebral aggregation of the
neurotoxic peptide Aβ [17]. Aβ is generated from the sequential
endoproteolysis of a longer precursor, amyloid precursor protein
(APP), by the action of two enzymes, β-secretase and γ-secretase.
Another enzyme, α-secretase, precludes Aβ production by cleaving
APP at the Aβ sequence [61]. Several proteases of the A Disintegrin
And Metalloproteinase (ADAM) family, such as ADAM10, have been
implicated in the α-secretase cleavage of APP. In 2006, we showed
that calorie restriction attenuates Aβ production, in part by promoting
α-secretase through mechanisms involving activation of SIRT1 [52,53].
Calorie restriction was found to increase SIRT1 expression and NAD+
levels in the brain of the Tg2576 transgenic mouse model of AD.
Furthermore, we found that SIRT1 expression in primary Tg2576
neurons and in APP-transfected Chinese hamster ovary (CHO) cells
reduces the generation of Aβ from APP by facilitating α-secretase
activity [52,53]. Additional work demonstrated that expression of
SIRT1 in the brain results in decreased Rho-associated protein kinase
ROCK1 expression and elevated secretase activity in vivo, implicating
ROCK1 in SIRT1-mediated α-secretase activity [52,53]. Moreover,
studies in squirrel monkeys demonstrated that calorie restriction in
primates also effectively reduces the contents of cortical Aβ peptides,
and that this decrease is inversely correlated with SIRT1 protein con-
centrations in the same brain region [52,53].
These results by Qin et al. were recently conﬁrmed in SIRT1 trans-
genic and knockout mice [20]. The authors found that Aβ production
and the resulting amyloid deposition is decreased in the brains
of SIRT1 transgenics. In contrast, both Aβ production and amyloid
deposition in the brain are elevated in SIRT1 knockouts when crossed
with APP-transgenic mice. Mice overexpressing SIRT1 also showed
a reduction in brain inﬂammation, tau phosphorylation (another
hallmark of AD), and in cognitive defects speciﬁc to the APP-
transgenic mice. Conversely, SIRT1 deﬁciency exacerbated Aβ-linked
pathology in the mice. In this study, SIRT1 was proposed to activate α-
secretase by directly activating ADAM10 expression. The authors
further demonstrated that SIRT1 can deacetylate and coactivate the
retinoic acid receptor β, a known modulator of ADAM10 transcrip-
tion [20]. Collectively, the original discoveries of Qin et al. [52,53],
and the conﬁrmatory studies from Donmez et al. [20], suggest that
pharmacological activation of SIRT1 may represent a promising
approach to preventing amyloid deposition and neurodegeneration
in AD [71,75].
7. A possible novel pathway for resveratrol-mediated responses in
the brain via AMPK activation and increased protein clearance
Our laboratory and others have recently found that resveratrol
controls Aβ accumulation by facilitating its proteolytic clearance in
neuronal cells [43,65,66] and reduces cerebral amyloid deposition
in vivo in APP transgenic mice [36,66]. We demonstrated, for the ﬁrst
time, that AMPK activation is responsible for the anti-amyloidogenic
effects of resveratrol [66]. AMPK is a heterotrimeric Ser/Thr protein
kinase that is activated by different upstream kinases such as liver
kinase B1 (LKB1) and Ca2+/CaM-dependent protein kinase kinase β
(CaMKKβ), a kinase predominantly expressed in neural tissue [14,24,
67]. AMPK controls protein degradation by inhibiting the protein kinase
mechanistic target of rapamycin (mTOR) and by activating autophagy
[26]. Our work revealed that resveratrol can activate AMPK by
increasing CaMKKβ-dependent phosphorylation of AMPK. Activation
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and proteolytic clearance of Aβ [66]. Importantly, we also demonstrated
that orally administered resveratrol inmice can cross theBBB to activate
brain AMPK and to reduce Aβ levels and deposition in the cerebral
cortex [66]. These studies highlight the therapeutic potential of AMPK
activation as an anti-amyloidogenic strategy in AD, but also motivate
the search for resveratrol metabolites/analogues or other polyphenolic
compounds (or polyphenolic preparations) with improved potency
and brain penetration properties as anti-neurodegenerative molecules
[65,71,75].
8. Caloric restriction, resveratrol and neurodegeneration
Resveratrol is known to have beneﬁcial metabolic effects and is
considered a mimetic of dietary/caloric restriction. Since resveratrol is
being considered for a treatment for HD, it is of high interest that Ho
et al. found beneﬁcial anti-diabetic effects of resveratrol in the mouse
model of HD. Chaturvedi et al. recently demonstrated that adminis-
tration of SRT501-M beneﬁts metabolic impairments observed in
N171-82Q mice by reducing levels of brown adipose tissue (BAT)
vacuolation and blood glucose, two metabolic parameters that are
abnormally elevated in this HD mouse model, although not all of the
HD mice responded to SRT501-M treatment [16]. In BAT, a transcrip-
tional response was observed in treated HD mice with an increase in
the expression of PGC-1α and two of its downstream effectors, nuclear
respiratory factor-1 (NRF-1) and uncoupling protein-1 (UCP-1).
Impaired PGC-1α function has also previously been shown to play a
role in muscle dysfunction [15] and mitochondrial dysfunction [79] in
HD. It is possible that resveratrol may improve the HD phenotype via
metabolic beneﬁts. However, since CNS-related indicators of HD were
not improved in the resveratrol-treated N171 mice, it appears that the
metabolic effects of resveratrol would not ameliorate CNS neurodegen-
eration. Moreover, an implication of the Ho et al. study is that caloric
restriction is unlikely to ameliorate central HD symptoms. In contrast
to HD, Wang et al. [72] demonstrated that caloric restriction does
attenuateβ-amyloid neuropathology and improves glucosemetabolism
in a mouse model of AD [72].
9. Mild cognitive impairment (MCI): an important target for
secondary prevention with polyphenol combination treatment
MCI is deﬁned as a syndromeof subjective and/or objective evidence
for cognitive deﬁcits with no evidence (or minimal evidence) of
functional decline [5]. MCI has been subtyped into amnestic MCI
(affecting memory) vs. nonamnestic MCI (affecting other cognitive
domains only). Individuals with amnestic MCI are at high risk of
developing incident AD [50], and most have signiﬁcant brain amyloidFig. 2. Bioactive dietary polyphenol preparation (BDPP), a novel nutraceutical combination des
matic identiﬁes the possible contribution of individual BDPP components for the prevention and
may beneﬁt AD dementia by promoting Aβ degradation and by decreasing neuroinﬂammatio
polyphenol preparations, will modulate additional ADmechanisms (e.g., Aβ synthesis, Aβ aggre
of therapeutic success.burden [35]. Since individuals with MCI are, by deﬁnition, functioning
well, it would be a substantial public health beneﬁt if interventions
could be found to prevent their progression to dementia (i.e., secondary
prevention of dementia). There is currently no FDA-approved inter-
vention for secondary prevention of MCI, and trials of current AD
treatments have failed (spectacularly) in this regard [55]. MCI deﬁnes
a risk group, not a disease state, and in fact, many individuals with
MCI do not progress to dementia or AD [44]; these individuals probably
do not have a brain disease. Given these observations, it is particularly
important for an intervention to be relatively safe and non-invasive.
Most of the interventions currently under investigation in this ﬁeld
are cognitive or behavioral interventions, with relatively few drug trials,
the most advanced of which is intranasal insulin, the investigation of
which is based on parallel hypotheses to ours [18,56]. Individuals with
MCI frequently have metabolic risk factors including insulin resistance
and prediabetes, and these individuals are at particular risk of cognitive
decline.
10. Prediabetes and cognition in the elderly and in individuals with
MCI: implications of resveratrol in the modulation of glucose
metabolism and in the prevention of MCI progression into frank
mild AD dementia
Prediabetes is a condition in which glucose levels are elevated, but
do notmeet the criteria for diabetes. In theU.S., approximately 29.1 mil-
lion adults have this condition [13]. These individuals are at higher risk
of developing diabetes and cardiovascular disease (CVD), and also are at
higher risk of death [3]. Prediabetes is also a risk factor for future cogni-
tive decline. One study found that individuals with prediabetes have
worse baseline cognitive scores compared to those with normal glucose
levels; their risk of developing clinically signiﬁcant cognitive impair-
ment (dementia, MCI, or very low cognitive score) in 4 years was al-
most two fold higher compared to those with normal glucose levels.
Interestingly, the risk of future cognitive impairment in individuals
with prediabeteswas as high as in thosewith T2D in this study [82]. An-
other longitudinal study found that MCI individuals with prediabetes
had an almost six fold higher risk of converting from MCI to AD com-
pared to MCI individuals with normal glucose levels. This effect was
even higher than the risk of converting to AD among MCI individuals
with T2D. One of the possible reasons for this effect may be that insulin
resistance and elevated glucose levels are often ignored for many years
in individuals with prediabetes [81]. Therefore, it is important to recog-
nize that individuals with prediabetes are at an insulin resistant state
that is in “the continuumofmetabolic disorders,” and that theywill like-
ly become diabetic in the future [40].
In light of these associations between insulin resistance and
cognition, the effects of intensive (HgA1C b 6.0%) and standardigned to simultaneously target multiple pathogenic mechanisms underlying AD. The sche-
therapeutic attenuation of AD dementia. Experimental evidence suggests that resveratrol
n. We further proposed that application of resveratrol, along with other bioactive dietary
gation, tau hyperphosphorylation, and tau aggregation), whichwill increase the likelihood
1207G.M. Pasinetti et al. / Biochimica et Biophysica Acta 1852 (2015) 1202–1208glycemic control (HgA1C 7.0–7.9%) on longitudinal cognitive function
were examined in the Action to Control Cardiovascular Risk in
Diabetes-Memory in Diabetes (ACCORD-MIND). Although higher
HbA1C, an indicator of average blood sugar levels over a period of
weeks/months, was associated with lower cognitive scores at baseline,
there were no differences in the cognitive scores between the intensive
and standard glycemic control groups at 20 and 40 month follow up
times [39]. Moreover, highermortality in the intensive glycemic control
group led to early termination of the study [4].
Consistentwith this evidence, a recent study testedwhether supple-
mentation with resveratrol can enhance memory performance in older
adults, and addressed potential mechanisms underlying this effect, in
the context of glucose metabolism [80]. The investigators found that
resveratrol supplementation in older adults leads to signiﬁcant
improvement in memory performance in association with improved
glucose metabolism, as indicated by decreased HbA1c, as well as
increased functional connectivity in the brain.
Therefore, novel strategies to address insulin resistance and cogni-
tive dysfunction in this population are needed. While MCI represents a
high risk group for conversion to AD, there is also a great variability
in the risk due to the heterogeneity of this population [21]. Hence,
identifying and targeting treatment towards a high risk subgroup of
MCI individuals such as those with prediabetes will allow for more
effective intervention.
11. Polyphenol combination therapy as a novel strategy to delay the
conversion of MCI into AD
BDPP(bioactive dietary polyphenol preparation) is a combination
of three bioactive and commercially available polyphenol products
(Concord grape juice, grape seed extract, and resveratrol), and is a
novel nutraceutical combination designed to provide three selective,
bioactive, polyphenol-rich dietary preparations to simultaneously
target multiple AD pathogenic targets, as well as metabolic syndrome
phenotypes (primarily through resveratrol action). As we describe in
more detail below, each of the BDPP components are capable of exerting
uniquemechanisms of action against AD pathogenicmechanisms. Thus,
in comparison to individual BDPP components, application of BDPP will
allow for amore comprehensive coverage of AD pathogenic targets, and
therefore is a more efﬁcacious strategy for treating patients with early
AD and prediabetes.
In ongoing studies in our laboratory, we found that BDPP targets
amyloid load, synaptic plasticity, and cognition in mouse models of AD
and metabolic syndrome [69]. Among MCI individuals, those with
prediabetes are at high risk of converting to AD. The advantages of
this nutraceutical include a benign adverse effect proﬁle, oral adminis-
tration, and a refreshing lack of intellectual property issues, which will
keep costs down. This is particularly relevant as we enter into an era
where we may be able to target prodromal and preclinical AD for
secondary prevention. Since secondary prevention, by deﬁnition,
involves treatment of a large population, it would be particularly useful
if an intervention for secondary preventionwas also inexpensive, which
is unlikely with the currently studied strategies (passive immunothera-
py and beta-secretase inhibition, for example). See Fig. 2 for a scheme of
theworking hypothesis regarding the possible application of resveratrol
along with other bioactive dietary polyphenols for the prevention and
therapeutic attenuation of AD dementia.
12. Conclusions
Although recent reports have shown that resveratrol and other
grape derived polyphenol metabolites can cross the BBB and lead to
some biological responses in the brain following oral dosing [1,28,36,
66], the important question of how to improve polyphenol, in particular
resveratrol, bioavailability in the brain remains to be addressed. Indeed,
should resveratrol be tested further, improved administration andformulation methods should be implemented, and more potent
resveratrol metabolites or analogues should be identiﬁed prior to
evaluation in animal models. Another line of research is to focus
on novel, brain-targeting grape-derived polyphenols with promising
anti-neurodegenerative properties [31,73].
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